FindTrial
Sign In

Anti-IgE Therapy for Kimura's Disease

Anti-IgE Therapy for Kimura's Disease - Anti-IgE Therapy for Kimura's Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000011354
Enrollment
3
Registered
2013-08-02
Start date
2012-09-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kimura&#39

Interventions

a fixed schedule of eight cycles of omalizumab 300 mg, administered subcutaneously at intervals of 2 weeks

Sponsors

Tokyo Women's Medical University, Department of Otorhinolaryngolog
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. patients aged >20 years old 2. patients who are unresponsive to standard therapies 3. Levels of serum IgE >30 4. patients agreed to prior written informed consent

Exclusion criteria

Exclusion criteria: 1. patients who are hypersinsitive to omalizumab 2. pregnenat or breast feeding patients 3. patients who are considered inadequate

Design outcomes

Primary

MeasureTime frame
Changes of mass lesion—

Countries

Japan

Contacts

Public ContactEri Sakitani

Tokyo Women's Medical University Department of Otorhinolaryngology

03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026